宮頸癌疫苗希瑞適在中國內地上市

The first imported batch of Cervarix, the cervical cancer vaccine, has passed quality inspections and is heading to health clinics across the Chinese mainland, pharmaceutical company GlaxoSmithKline (GSK) said recently.

製藥企業葛蘭素史克日前表示，中國內地進口的首批宮頸癌疫苗希瑞適已通過質檢，正運往各地的衛生診所。

Cervarix was approved by the China Food and Drug Administration in July last year.

希瑞適是在去年7月獲得的國家食品藥品監管總局的批准。

The vaccine is registered in 132 countries and regions, and more than 69m doses have been provided to the global market, according to GSK.

據葛蘭素史克介紹，該公司已在132個國家及地區對希瑞適進行了註冊，並已向全球市場供應超過6900萬劑該疫苗。

"Cervical cancer is the third most common cancer among Chinese women aged 15 to 44. There are 100,000 new cases of cervical cancer in China each year, and 30,000 deaths due to the disease," said Qiao Youlin, a top epidemiologist.

著名流行病學家喬友林稱：“宮頸癌是我國15歲至44歲女性中第三大高發癌症，全國每年新發病例10萬，死亡病例3萬。”

"For this reason, cervical cancer vaccination, together with cervical cancer screening, will significantly reduce the incidence of cervical cancer and precancerous lesions," he said.

他說道：“因此，在開展宮頸癌篩查的同時，宮頸癌疫苗接種將顯著降低宮頸癌及其癌前病變的發病率。”